Isofol Medical (ISOFOL) investor relations material

Executive summary

• Transitioned from planning to execution phase with a successful, fully guaranteed and oversubscribed rights issue, raising SEK 91 million gross and strengthening the financial position for continued clinical development.

• Positive progress in the phase Ib/II clinical study for arfolitixorin, with the first cohort completed and the next dose level initiated.

• Constructive pre-IND meeting with the FDA validated the clinical development plan for arfolitixorin in the U.S.

• Japanese partner Solasia Pharma K.K. to finance and conduct phase II/III studies in Japan, expanding the clinical program's reach.

• Participation in major scientific and business conventions, and establishment of a new advisory board.

Financial highlights

• No revenue reported; net loss for Q2 was SEK -14.7 million, compared to SEK -11 million in Q2 last year; H1 2025 net loss was SEK -28.3 million, up from SEK -19.5 million year-over-year.

• Cash and cash equivalents at June 30, 2025, were SEK 65.7 million, down from SEK 119.2 million a year earlier, prior to the rights issue completed in July.

• Cash flow for the quarter was SEK -17 million, compared to SEK -9 million the previous year.

• Operating costs increased due to higher personnel and external costs related to clinical studies.

• No loans or material investments; R&D costs expensed as incurred.

Outlook and guidance

• Strengthened cash position post-rights issue provides funding for at least the next 12 months.

• Ongoing phase Ib/II study to continue with escalating doses and potential expansion to Japan in 2026.

• Clinical trial is progressing as planned, with updates to be provided as cohorts advance.

• Further updates on clinical progress and business development expected throughout the year.